key: cord-0308723-utp4bpxt
authors: Hernandez, M. M.; Banu, R.; Gonzalez-Reiche, A. S.; Gray, B.; Shrestha, P.; Cao, L.; Chen, F.; Shi, H.; Hanna, A.; Ramirez, J. D.; van de Guchte, A.; Sebra, R.; Mount Sinai Pathogen Surveillance Study Group,; Gitman, M. R.; Nowak, M. D.; Cordon-Cardo, C.; Schutzbank, T. E.; Simon, V.; van Bakel, H.; Sordillo, E. M.; Paniz Mondolfi, A. E.
title: RT-PCR/MALDI-TOF diagnostic target performance reflects circulating SARS-CoV-2 variant diversity in New York City
date: 2021-12-07
journal: nan
DOI: 10.1101/2021.12.04.21267265
sha: a55a453dbd6771bf05ea29aba3365e947b83da85
doc_id: 308723
cord_uid: utp4bpxt

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to circulate, multiple variants of concern (VOC) have emerged. New variants pose challenges for diagnostic platforms since sequence diversity can alter primer/probe binding sites (PBS), causing false-negative results. The Agena MassARRAY SARS-CoV-2 Panel utilizes reverse-transcription polymerase chain reaction and mass-spectrometry to detect five multiplex targets across N and ORF1ab genes. Herein, we utilize a dataset of 256 SARS-CoV-2-positive specimens collected between April 11, 2021-August 28, 2021 to evaluate target performance with paired sequencing data. During this timeframe, two targets in the N gene (N2, N3) were subject to the greatest sequence diversity. In specimens with N3 dropout, 69% harbored the Alpha-specific A28095U polymorphism that introduces a 3'-mismatch to the N3 forward PBS and increases risk of target dropout relative to specimens with 28095A (relative risk (RR): 20.02; p<0.0001; 95% Confidence Interval (CI): 11.36-35.72). Furthermore, among specimens with N2 dropout, 90% harbored the Delta-specific G28916U polymorphism that creates a 3'-mismatch to the N2 probe PBS and increases target dropout risk (RR: 11.92; p<0.0001; 95% CI: 8.17-14.06). These findings highlight the robust capability of Agena MassARRAY SARS-CoV-2 Panel target results to reveal circulating virus diversity and underscore the power of multi-target design to capture VOC.

Since the recognition and global spread of coronavirus disease 2019 , nucleic acid 50 amplification testing has been the diagnostic mainstay for identifying new severe acute respiratory 51 syndrome coranvirus-2 (SARS-CoV-2) infections. Historically, the majority of diagnostic target primers 52 and probes have been designed from viral genomes characterized early in the pandemic. However, in the 53 two years since the first SARS-CoV-2 genome was identified, viral variants have emerged in response to 54 various evolutionary pressures 1,2 . Emergence of variants of concern (VOC) and of interest (VOI) poses 55 a hurdle for diagnostic assays as sequence variation generates mismatches to primer/probe binding sites 56 (PBSs), potentially causing target dropout and false-negative results 3,4 . Failure to promptly detect 57 infections with emerging variants that may be associated with greater transmissibility and infectivity 58 represents a substantive risk for forward transmission in the community. 59

The diagnostic assays that are most robust for detection of SARS-CoV-2 and least affected by 60 viral sequence changes are designed to amplify two or more targets across different viral genes (e.g., 61 open reading frame 1ab (ORF1ab), nucleocapsid (N), spike (S), and envelope (E)). This redundancy can 62 compensate for individual target dropout due to inherent biochemical differences and analytical 63 sensitivities among targets or due to emergent viral genome diversity at PBS sequences. Several groups 64 have demonstrated the utility of platforms with multiple targets to accurately detect emerging SARS-65

CoV-2 variants 3,5,6 . Furthermore, target performance patterns on these platforms can be used to 66 elucidate dynamics of circulating variants in communities. Indeed, multiple reports described the use of 67 dropout of diagnostic targets designed at S 5, 7, 8 or N 9 genes as a screen for PBS-specific polymorphisms 68 that have arisen among emergent SARS-CoV-2 viruses such as the Alpha variant (B.1.1.7 lineage). 69

In early 2021, the Delta variant (B.1.617.2 lineage) of SARS-CoV-2 surged in India 10-12 , and 70 soon Delta and its sublineages (AY.x) quickly spread across the globe 2,13-15 . By Fall 2021, despite 71 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 increased vaccination rates and infection prevention methods [16] [17] [18] , Delta and its sublineages became 72 predominant in New York City (NYC) and abroad 10, 13, 14 . Given that emergent variants may be 73 associated with resistance to therapeutic antibodies 19, 20 , increased transmissibility 12, 16, 21, 22 , or reduced 74 vaccine effectiveness 16, 17, 23, 24 , diagnosing new infections is vital. Several mutation-specific assays have 75 been designed to detect lineage-specific S gene mutations in Delta and older variants [25] [26] [27] . However, few 76 assays have been evaluated for their ability to capture contemporary variants in routine clinical settings, 77 or to shed light on sequence diversity in virus genes other than Spike (S). 78

We recently reported the power of the Agena MassARRAY® SARS-CoV-2 Panel for detection 79 of emergent SARS-CoV-2 variants in NYC during the first months of 2021 and the utility of diagnostic 80 target performance to illuminate sequence diversity among then-predominant Alpha variant genomes 28 . 81

This assay combines reverse-transcription polymerase chain reaction and matrix-assisted laser 82 desorption-ionization time-of-flight mass spectrometry (RT-PCR/MALDI-TOF) to detect five targets in 83 the SARS-CoV-2 genome. Coincident with the spread of the Delta VOC in NYC, we observed a distinct 84 change in the target performance patterns that reflect ongoing viral evolution, prompting us to examine 85 the corresponding genomic sequence data. 86

For the current study, we compared paired RT-PCR/MALDI-TOF diagnostic target data and 87 genome sequencing data for SARS-CoV-2-positive specimens that were collected from April 11, 2021 -88 August 28, 2021, and recovered, deidentified, and  subset of 256 were deidentified and underwent SARS-CoV-2 next-generation sequencing as previously 105 described [28] [29] [30] . For this retrospective study, we utilized deidentified data for diagnostic specimens tested 106 on the Agena MassARRAY ® SARS-CoV-2 Panel and MassARRAY ® System (Agena, CPM384) 107 platform. Details of processing and SARS-CoV-2 testing of upper respiratory and saliva specimens have 108 been described previously 28, 31 . 109

This RT-PCR/MALDI-TOF assay detects five viral targets: three in the nucleocapsid (N) gene 110 (N1, N2, N3) and two in the ORF1ab gene (ORF1A, ORF1AB). Results were interpreted as positive if ≥ 111 2 targets were detected or negative if < 2 targets were detected. If no MS2 internal extraction control 112 (IC) and no targets were detected, the result was invalid and required repeat testing of the specimen 113 before reporting. If IC was detected and no targets were detected, the sample was interpreted as 114 negative. 115 116 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 SARS-CoV-2 sequencing, assembly and phylogenetic analyses 117 SARS-CoV-2 viral RNA underwent reverse-transcription, PCR amplification and next-118 generation sequencing followed by genome assembly and lineage assignment using a phylogenetic-119 based nomenclature as described by Rambaut et al. 32 (Table S1) 34 . We generated reverse-127 complement sequences for reverse primers for all five targets and probes that are designed in the reverse 128 orientation (e.g., N1-N3). An unaligned FASTA file including sequence data for the clinical specimens 129 and the Wuhan-Hu-1 reference sequence (NCBI nucleotide: NC_045512.2 (Genbank: MN908947.3)) 130 was generated for each of the fifteen primers/probes. Alignment of specimen sequences with each 131 primer/probe sequence was performed using the Multiple Alignment using Fast Fourier Transform 132 (MAFFT) platform 35, 36 as previously described 28 . To enable inclusion of incomplete genomes that had 133 intact regions sequenced at PBSs, we did not remove uninformative sequences (e.g., with ambiguous 134 letters). Otherwise, the default settings were used to align all sequences to the reference genome, which 135 generated a resulting FASTA alignment file for each primer and probe sequence. 136 137 Sequence variation in primer/probe target regions 138 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 To examine sequence diversity at each primer/probe PBS region, nucleotide diversity per 139 basepair was calculated using the PopGenome population genomics analysis package in R (v4.1.2) 37 . 140

Nucleotide diversity per site (π) was calculated by dividing the nucleotide diversity of all sequences 141 within each PBS sliding window by the number of nucleotide sites in each corresponding PBS. 142

To identify and calculate mismatch frequency at each PBS, custom Unix-code 38 was used to 143 identify mismatches at each nucleotide position within each primer and probe sequence as descried 144 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10. 1101 For statistical comparison of fraction of PBS with mismatches in genomes with detected targets 161 versus those with dropout, normality was assessed by D'Agostino and Pearson test (GraphPad Prism 162 v9.2.0). All distributions were non-parametric, and thus, a Mann-Whitney test (two-tailed) was 163 performed (GraphPad). To determine if specific mismatches were associated with specific target dropout 164 results, specimens were grouped by (1) presence or absence of the mismatch of interest (in the setting of 165 no other mismatches) and (2) detection or dropout of the target of interest -which resulted in a 2x2 166 contingency table which underwent association testing by Fisher's exact test. In addition to p-value, 167 relative risk (RR) ratios and 95% confidence intervals (CI) are provided for association testing. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.04.21267265 doi: medRxiv preprint

Of 448 SARS-CoV-2-positive specimens, 117 (26%) had all five targets detected with the 176 remaining having one (n=247) or more (n=84) targets dropout. For the subset of 256 SARS-CoV-2-177 positive specimens sequenced in our study, all five diagnostic targets were detected in 96 (38%), with 178 the remaining having one (n=140) or more (n=20) targets dropout (Table S2) . 179

When we calculated weekly detection rates for individual targets among these SARS-CoV-2-180 positive specimens, the N2 (0.61) and N3 (0.77) targets had the lowest average detection rates ( Figure  181 1A). Notably, N2 and N3 detection rates were lowest at distinct periods of time. Among weeks with ≥ 3 182 SARS-CoV-2-positive specimens sequenced, the N2 detection rate was lowest (0.13) in the week ending 183

July 31, and the N3 detection rate was lowest (0.41) in the week ending May 1. We hypothesized this 184

shift was due to changes in the population of circulating SARS-CoV-2 variants. When we compared 185 individual target detection rates to reported prevalence of variants in NYC during the same time period, 186 we found the N3 detection rate was lowest when the Alpha variant (B.1.1.7 + Q.x) was predominant at 187 33% ( Figure 1B) . Similarly, the N2 detection rate was lowest when the Delta variant (B.1.617.2 + 188 AY.x) comprised 96% of circulating SARS-CoV-2 in NYC. Given these findings, we used diagnostic 189 target and paired genome sequence data to identify mismatches to Agena MassARRAY ® target PBSs to 190 determine impact of SARS-CoV-2 genomic diversity on diagnostic target performance. was perfect complementarity (0 mismatches) between genome sequences and forward, reverse, and 197 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021.

probe sequences for almost all (>99%) specimens. However, for specimens in which the N2 target was 198 detected, mismatches occurred both at N2 forward (34.3%) and reverse (46.6%) PBSs ( Figure 2B) . 199

Specifically, among specimens with detectable N2 target, 1-3 mismatches to the forward PBS and up to 200 1 mismatch to the reverse PBS were observed. 201

Notably, specimens with N2 target dropout had a significantly greater number of mismatches to 202 the N2 probe PBS ( Figure 2B ). The same was found for specimens with N3 dropout and mismatches to 203 the N3 forward PBS ( Figure 2C ). Of interest, more mismatches to the N2 reverse PBS were found for 204 specimens in which the N2 target was detected than for those with N2 dropout. Indeed, the majority of 205 specimens with detectable N2 target (85%) harbored mismatches in N2 forward or reverse PBSs, but 0% 206 of specimens with detectable N2 target harbored mismatches to the N2 probe PBS. 207 208

Because mismatch position in PBSs can affect primer/probes binding to target sites [40] [41] [42] [43] , we 210 characterized mismatch frequencies by position in each PBS (Figure 2 ). At least one mismatch was 211 identified in every target PBS with the exception of the N1 reverse, N3 reverse, and the ORF1AB 212 forward primers which had zero mismatches to all possible haplotypes in our dataset. To assess the level 213 of sequence diversity across each target, we calculated the nucleotide diversity per site (π) for each PBS 214 sequence. Overall, genomes sequenced in this timeframe demonstrated the most diversity at N2 target 215 PBSs (≥0.01260) followed by the N3 forward PBS (0.01075) (Figure 3B -C). Diversity at these targets 216 was at least seven-fold more than that at all other target PBSs. Notably, this diversity corresponded with 217 a predominance of Delta (56.7%), Alpha (15.7%), , and Iota (16.5%) variant genomes in this dataset. 218

To identify individual mismatches associated with target dropout, we measured the proportion of 219 genomes with a mismatch at each PBS position and compared this level across specimens that yielded 220 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.04.21267265 doi: medRxiv preprint target detection or dropout ( Figure S1 ). From 5'-to-3' direction, there were mismatches to 1 st -3 rd bp of 221 the N2 forward primer PBS (SARS-CoV-2 genome positions 28881 -28883) in genomes that yielded 222 both N2 target detection and dropout ( Figure 3B , Figure S1B ). Overall, there were 192 specimens with 223 at least one mismatch to the first 3 bp of the N2 forward primer. Of these, 49 (26%) had a concurrent 224 trio of substitutions in the N gene: G28881A, G28882A, and G28883C; the remaining 143 (74%) 225 harbored a single G28881U substitution. The GGG-to-AAC and the G28881U substitutions were 226 independent of one another and no combinations of the two were detected. The majority of specimens 227 with the trio (88%) had detectable N2 target. In contrast, 78% of specimens with G28881U resulted in 228 dropout which -despite its position at the 5'-end of the N2 forward primer -represents a significant 229 association of G28881U with N2 target dropout (p<0.0001). 230

Interestingly, of 123 genomes with N2 target dropout we identified 111 (90%) that harbored a 231 mismatch at the terminal 3' base of the 22-bp-long N2 probe ( Figure 3B, Figure S1B ). All mismatches 232 are the result of a guanine-to-uracil substitution in the N gene (G28916U). This substitution was not 233 identified among any of the 131 specimens with detectable N2 target. In fact, the relative risk of N2 234 target dropout in the setting of the G28916U substitution was 11.9-times greater than genomes with the 235 native guanine (p<0.0001; 95% CI: 8. 17-14.06 ). We also determined that all 111 genomes with the 236 G28916U substitution have the G28881U substitution. The linkage of the G28881U and G28916U 237 polymorphisms likely explains why the former -a 5'-end mismatch to the N2 forward PBS -is 238 associated with N2 target dropout. Indeed, 100% of genomes (n=32) that possess the G28881U 239 substitution alone resulted in N2 target detection. 240

In the current study, of 36 specimens with N3 target dropout, 25 (69%) had a mismatch at the 241 penultimate position of the 3'-end of the 20-bp-long N3 forward primer ( Figure 3C, Figure S1C ). This 242 mismatch corresponded with the adenine-to-uracil substitution in the ORF8 gene (A28095U) which 243 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.04.21267265 doi: medRxiv preprint causes a 20-fold risk of N3 target dropout relative to genomes with the native nucleotide (p<0.0001; 244 95% CI: 11.36-35.72) which is consistent with our findings earlier in the pandemic 28 , prior to the 245 current study period. 246

We assessed whether the associations between mismatch and corresponding target dropout 247 persist when quantity of virus genomic material in specimens is controlled as previously described 28 . 248

When analyses are limited to specimens for which all non-N2 targets are detected, the association of the 249 G28916U substitution with N2 dropout remains significant (p<0.0001; RR: 20.2; 95% CI: 14.58-47.48) . 250

In addition, when analyses are limited to specimens for which all non-N3 targets are detected, the 251 A28095U substitution remains significantly associated with N3 target dropout (p<0.0001; RR: 31.03; 252 95% CI: 10.95-91.10). These results indicate that the G28916U and A28095U substitutions are 253 associated with N2 and N3 target dropout, respectively, independent of quantity of SARS-CoV-2. 254 255

To determine whether target dropout was the result of lineage-specific variation, we examined 257 phylogenetic lineages of genomes harboring the distinct polymorphisms. Among 25 specimens with N3 258 target dropout in this study, 23 (92%) belonged to the B.1.1.7 lineage (Alpha variant) and 2 were partial 259 genomes whose phylogenies could not be determined. These specimens were collected from April 11, 260 2021 (PV36791) through June 30, 2021 (PV37690), which mirrored the prevalence of the Alpha variant 261 in NYC ( Figure 1B) . 262

We next examined the lineage of genomes harboring the G28916U substitution (Figure 4) . Of 263 111 specimens that bore the G28916U polymorphism and resulted in N2 target dropout, the earliest was 264 from July 1, 2021 (PV37692) and the latest from August 21, 2021 (PV38720). All genomes 265 corresponded with lineages and sublineages of the Delta variant. Specifically, these included the 266 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.04.21267265 doi: medRxiv preprint B.1.617.2 (n=67) lineage and AY.20 (n=2), AY.23 (n=1), AY.25 (n=22), AY.3 (n=17), AY.33 (n=1), 267 and AY.5 (n=1) sublineages. We did not find the G28916U substitution among any of the other variant 268 lineages in our dataset ( Figure 4A) . 269

We broadened our analyses to interrogate SARS-CoV-2 genomes deposited globally for the 270 G28916U polymorphism. We utilized the publicly-available EpiCoV (GISAID) database and queried 271 2,103,844 sequences collected during the same timeframe of this study (Figure 4B) . We found the Delta CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10. 1101 Discussion 282

In the current study, we present a robust assessment of the impact of emergence of SARS-CoV-2 283 variants on detection of individual target genes included in the Agena MassARRAY ® SARS-CoV-2 284

Panel, focusing on a five-month period characterized by rapid changes in circulating VOC and VOI. 285

Molecular diagnostic tests to detect SARS-CoV-2, first designed almost two years ago, are 286 challenged by continued viral circulation and rapid viral diversification, with continual emergence of 287 new lineages. At the same time, recognition that some virus variants can demonstrate increased 288 infectivity and disease severity among a broader population that now includes younger individuals 289 2,13, 16, 17, 44 has raised awareness regarding assay sensitivity and risks for missed diagnoses. Although 290 several studies have reported the impacts of viral sequence variation on conventional diagnostic 291 platforms 5, 7, 27, 45 or have highlighted, in silico, potential interference of variant polymorphisms with 292 publicly-available target sequences 42, 46, 47 , there are limited reports on assay performance in actu for 293 detection of the Delta VOC and sublineages, and other recent VOC/VOI. 294

We utilized publicly-available primer/probe sequences of the Agena MassARRAY ® SARS-CoV-295 2 Panel and a deidentified dataset from clinical specimens that included individual target detection data 296 and whole-genome sequencing to generate a snapshot of virus sequence diversity at each target PBS and 297 to determine the extent to which polymorphisms are associated with individual target performance. 298

Interestingly, we found that distinct viral substitutions resulted in N2 and N3 target dropout. Consistent 299 with what we previously reported 28 , the A28095U substitution is a B.1.1.7-associated polymorphism 300 that introduces a mismatch at the 3'-end of the N3 forward PBS which results in N3 target dropout. 301

Notably, a marked change in the pattern of target dropout occurred during the course of the study with 302 the introduction of the Delta VOC; we found the G28916U polymorphism unique to a subset of Delta 303 variants results in a 3'-mismatch to the N2 probe and is associated with N2 dropout. Our findings 304 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.04.21267265 doi: medRxiv preprint highlight the robust capability of this multiple-target platform to capture diverse viral variants, as well as 305 the ability of target performance to reflect lineage-specific sequence variation outside the conventional S 306 gene. 307 A number of recent reports have focused on variant panels designed to target a finite number of 308 emergent mutations to discern variant identity, particularly in the first months of 2021. Most panels 309 utilize RT-PCR or novel isothermal technologies (e.g., RT-LAMP, CRISPR/Cas-based, mass-310 spectrometry) to target specific polymorphisms in the S gene that have been ascribed to each of these 311 variants 25, 27, 45, [48] [49] [50] . However, a recent deep analysis of circulating variants across the globe revealed 312 that most of these signature mutations are not under positive selection 1 . Therefore, other than a finite 313 number of mutations in the spike protein (e.g., N501Y, S477N, V1176F, N501Y), one can anticipate 314 that other variant-defining polymorphisms may not persist over continued circulation of SARS-CoV-2 315 and, thus, new target formulations will need to be continuously considered. As most efforts to 316 accommodate new variants have been to redesign primers and probes or include more targets in this 317 region 45,51 , this may become impractical as inclusion of additional reactions can become costly and 318 introduce more room for error. Furthermore, although multiplexing assays allow for single-pot reactions, 319 the level of target redundancy is limited by the optical detection system as more fluorophores complicate 320 conventional diagnostic methods 52-54 . Therefore, as the COVID-19 pandemic continues and new 321 variants emerge, there can be great utility in existing assay platforms that target multiple regions outside 322 the S gene. 323 Our findings also highlight the level of sequence diversity observed at each of these five target 324 loci among sequences from VOC/VOI detected through August 2021. Among the Agena MassARRAY ® 325 SARS-CoV-2 Panel, N gene targets (e.g., N2, N3) are challenged by the greatest level of nucleotide 326 diversity which can result in dropout of each. Consistent with phylogenetic analyses of global sequences 327 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.04.21267265 doi: medRxiv preprint 1 , the N2 target region has the greatest sequence diversity. Although, a number of polymorphisms in the 328 N gene are under positive selection 1,46,55 , the evolutionary pressures exerted on A28095U (ORF8|K68*) 329 and G28916U (N|G215C) polymorphisms have not demonstrated positive selection or purported 330 epistatic interactions 1, 16 . This is likely due to the earlier timeframes for which each of these 331 phylogenetic studies were performed (e.g., December 2020 through May 2021) and the lack of robust 332 functional genomic studies in SARS-CoV-2. Thus, the fate of each of these polymorphisms is unclear 333 among emergent VOC, and each should be taken into consideration for use of this diagnostic platform 334 and others that target the same N gene regions going forward. 335

As SARS-CoV-2 variants continue to arise, robust platforms with high target redundancy for 336 virus detection and diagnosis are vital to capture new or existing lineages. As contemporary 337 polymorphisms undergo selection, evaluation of diagnostic target performance in the clinical setting can 338 help elucidate ongoing viral dynamics in patient communities and highlight platform target 339 combinations that should be further optimized. Lastly, our results reinforce the need for continuing 340 surveillance of assay target result patterns to increase the sensitivity of current molecular tests for 341 SARS-CoV-2 detection and to assure the adequate diagnosis of COVID-19 worldwide. 342 343 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. Griesmacher A, Aberle SW, Görzer I. Inadequate design of mutation detection panels prevents 460

interpretation of variants of concern: results of an external quality assessment for SARS-CoV Microbiol, 2020, 5:1403-7 487 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Acknowledgments 560

We thank the members of MSHS MML, Simon, and van Bakel laboratories for providing any assistance 561 when needed throughout this study. We are grateful for the continuous expert guidance provided by the 562 ISMMS Program for the Protection of Human Subjects (PPHS). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 M.M.H. and A.E.PM are the guarantors of this work and, as such, had full access to all of the data in the 582 study and take responsibility for the integrity of the data and the accuracy of the data analysis. 583 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.04.21267265 doi: medRxiv preprint Health surveillance data within the same timeframe. 597 598 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.04.21267265 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; where tail to arrowhead reflects 5' to 3' directionality. Grey boxes with black dotted borders outline 617

PBSs. Dots represent conserved nucleotides at each position and mismatched nucleotides are indicated. 618 PBS mismatches are indicated by arrows; red arrows reflect mismatches that are significantly associated 619 with target dropout. Notably, the association of the G28881U mismatch to the N2 forward PBS (panel 620 C, red "(U)") with target dropout is distinguished from the G28881A mismatch. Nucleotide diversity (π) 621 of sequences at each PBS is indicated. 622 623 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.04.21267265 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.04.21267265 doi: medRxiv preprint Week Ending (2021) No. Sequenced 45 14 17 15 12 4 2 1 0 4 0 3 3 2 2 8 16 47 62 3 No. Positive 63 18 20 23 30 10 7 1 0 4 0 3 6 5 7 18 30 83 107 13 A B . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 7, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10. 1101 

New York City Department of Health. COVID-19: Data. NYC Health COVID-19: Data on 397

The Pango Lineage Nomenclature

COVID-19 Genomics UK (COG-UK) Consortium11 ‡

CoV-2, and vaccine effectiveness associated with the Delta variant

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against 412 COVID-19-Associated Hospitalizations Among Immunocompromised Adults -Nine States

Association Between mRNA Vaccination and COVID-19

Hospitalization and Disease Severity

Reduced 425 neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Reduced sensitivity of SARS-CoV-2 431 variant Delta to antibody neutralization

SARS-CoV-2 variant Delta rapidly 435 displaced variant Alpha in the United States and led to higher viral loads

Early epidemiological signatures 440 of novel SARS-CoV-2 variants: establishment of B.1.617.2 in England

pangolin: lineage 489 assignment in an emerging pandemic as an epidemiological tool

Inc. MassARRAY® SARS-CoV-2 Panel Instructions for Use

MAFFT: a novel method for rapid multiple sequence 493 alignment based on fast Fourier transform

Bioinformatics resources for SARS-CoV-2 495 discovery and surveillance

PopGenome: an efficient Swiss army 497 knife for population genomic analyses in R

MM. AceM1188/SACOV_primer-probe_analyses. Zenodo

Plot Multiple Sequence Alignment using "ggplot2

Effects of primer-502 template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 503 model studies

Single-nucleotide polymorphisms and other 505 mismatches reduce performance of quantitative PCR assays

Mutations on COVID-19 diagnostic targets

Sequence variation in primer targets affects the accuracy of viral 509 quantitative PCR

Hospitalizations Associated with COVID-19 Among Children

MMWR Morb Mortal 516 Wkly Rep

The interplay of SARS-CoV-2 521 evolution and constraints imposed by the structure and functionality of its proteins

Deepening of In Silico Evaluation of SARS-CoV-2 Detection RT-qPCR 525 Assays in the Context of New Variants

Multiplex 527 Target-Redundant RT-LAMP for Robust Detection of SARS-CoV-2 Using Fluorescent Universal 528 Displacement Probes

Optimization and validation of RT-LAMP 531 assay for diagnosis of SARS-CoV2 including the globally dominant Delta variant

N1_Probe N1_Rev   Seq  Hap_1  Hap_2  Hap_3  Hap_4  Hap_5  Hap_6  Hap_7  Hap_8   28654  28761   All  243  3  2  2  1  1  1  1   Alpha  35  3  ------1 N3_Probe N3_Rev N2_Probe N2_Rev